Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
about
LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinomaIntra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?
P2860
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@ast
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@en
type
label
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@ast
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@en
prefLabel
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@ast
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@en
P2860
P356
P1433
P1476
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
@en
P2093
Hilary Glen
P2860
P304
P356
10.2217/FON-2016-0215
P407
P577
2016-06-24T00:00:00Z